Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286199 | 0.78 | ALDH1A1 (0.40) | KDM4EMAPK1HIF1AALDH1A1MEN1 | |
| SCHEMBL1687734 | 0.77 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL19658369 | 0.77 | KDM4E (0.46) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL10784050 | 0.76 | EPHX1 (0.58) | MEN1KMT2ACASP2 | |
| SCHEMBL854713 | 0.75 | ADRA1A (0.45) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL19495294 | 0.74 | PAOX (0.57) | KDM4EMAPK1HIF1APAOXMEN1 | |
| SCHEMBL10963060 | 0.74 | EPHX1 (0.61) | ALDH1A1CASP2 | |
| SCHEMBL14990106 | 0.74 | PAOX (0.43) | KDM4EMAPK1HIF1APAOXACHE | |
| SCHEMBL25477681 | 0.72 | SMN1; SMN2 (0.36) | KDM4EMAPK1HIF1AALDH1A1MEN1 | |
| SCHEMBL24388044 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Cellix Bio Provate Limited (IN) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | KDM4E 3790/4885MAPK1 3709/4885HIF1A 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.